![](/img/cover-not-exists.png)
249 Preclinical efficacy of the PARP inhibitor rucaparib (CO-338/AG014699/PF-01367338) in pancreatic cancer models with homologous recombination deficiencies (HRD)
Robillard, L., Lin, K., Lopez-Casas, P.P., Hidalgo, M., Harding, T.C.Volume:
50
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/S0959-8049(14)70375-2
Date:
November, 2014
File:
PDF, 58 KB
english, 2014